Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies

Hsin-Fang Tu,Margaret Wong,Ssu-Hsueh Tseng,Nattha Ingavat,Pola Olczak,Kin Israel Notarte,Chien-fu Hung,Richard B.S. Roden

DOI: https://doi.org/10.1186/s13048-023-01325-9

2024-01-19

Journal of Ovarian Research

Abstract:MUC16 is a heavily glycosylated cell surface mucin cleaved in the tumor microenvironment to shed CA125. CA125 is a serum biomarker expressed by > 95% of non-mucinous advanced stage epithelial ovarian cancers. MUC16/CA125 contributes to the evasion of anti-tumor immunity, peritoneal spread and promotes carcinogenesis; consequently, it has been targeted with antibody-based passive and active immunotherapy. However, vaccination against this self-antigen likely requires breaking B cell tolerance and may trigger autoimmune disease. Display of self-antigens on virus-like particles (VLPs), including those produced with human papillomavirus (HPV) L1, can efficiently break B cell tolerance.

reproductive biology

What problem does this paper attempt to address?

### Problems Addressed by the Paper

The paper primarily explores the development of a novel vaccine targeting the surface protein MUC16 (membrane-associated mucin) on ovarian cancer cells. Specifically:

1. **Background and Challenges**:
- Ovarian cancer is one of the most lethal gynecological cancers, with early diagnosis being difficult and most patients being in the late stages at the time of diagnosis.
- There is currently no reliable screening method for early detection of ovarian cancer.
- MUC16 is a highly glycosylated cell surface protein that is abundantly expressed on the majority of ovarian cancer cells and releases fragments known as CA125 as serum markers.
- Although CA125 can be used as a serum marker to monitor treatment efficacy, its predictive ability is insufficient for screening purposes.

2. **Research Objectives**:
- Develop a new vaccine strategy that displays a specific epitope (20 amino acids long) of MUC16 on virus-like particles (VLPs) to break tolerance to self-antigens.
- Induce a high-titer antibody response to specifically recognize and attack ovarian cancer cells.

3. **Specific Experimental Methods**:
- Use human papillomavirus (HPV) L1 protein to self-assemble into VLPs and display the 20 amino acid epitope of MUC16 through genetic insertion or chemical conjugation.
- Evaluate the efficacy of different vaccine strategies in mouse models, including DNA vaccines and VLP-based vaccines.

4. **Expected Results**:
- The study suggests that displaying the near-membrane epitope of MUC16 on VLPs can effectively break immune tolerance and induce an antibody response against ovarian cancer cells.
- Mice that were chemically conjugated with the MUC16 epitope produced higher antibody titers, especially when L1-RG1-VLPs were used for conjugation.

Through these studies, the authors aim to develop a new, efficient vaccine strategy for the prevention or treatment of ovarian cancer.